phase 3_completion
saveCellCarta Biosciences Inc — elranatamab (Phase III Trial Completion)
community read0 votes
Therapy area: Oncology. Indication: Multiple Myeloma (Kahler Disease), Refractory Multiple Myeloma, Relapsed Multiple Myeloma
Data sources
globaldata
Found something off?
drug timeline · 7
- approvalELREXFIO (ELRANATAMAB) — FDA approvalMar 25, 2026 · 197d ago
- approvalELREXFIO (ELRANATAMAB) — FDA approvalFeb 19, 2026 · 231d ago
- approvalELREXFIO (ELRANATAMAB) — FDA approvalJul 10, 2025 · 455d ago
- approvalELREXFIO (ELRANATAMAB) — FDA approvalJul 8, 2025 · 457d ago
- approvalELREXFIO (ELRANATAMAB) — FDA approvalSep 10, 2024 · 758d ago
- approvalELREXFIO (ELRANATAMAB) — FDA approvalDec 13, 2023 · 1030d ago
- approvalELREXFIO (ELRANATAMAB) — FDA approvalAug 14, 2023 · 1151d ago
comments(0)
5-min edit window · permanent after that